• Email
  • Help

Questions & Answers

On 5 October 2017,the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion*, recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product SevoFlo. The marketing authorisation holder for this veterinary medicinal product is Zoetis Belgium SA.

SevoFlo is currently authorised as an inhalation vapour, liquid for dogs. The variation concerns the addition of a new non-food producing target species (cats). SevoFlo is intended for the induction and maintenance of anaesthesia.

Detailed conditions for the use of this product are described in the updated summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

*Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Name Language First published Last updated
CVMP post-authorisation summary of positive opinion for SevoFlo (English only) 2017-10-06  

Key facts

Product details for SevoFlo
INN or common name


Active substance


Date opinion adopted05/10/2017
Company name

Zoetis Belgium SA

Application typePost authorisation